News & Updates
Showing Pharmacy articles
Showing
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.
Gedatolisib-based regimens boost PFS in HR+/HER2– PIK3CA-WT ABC
21 May 2026
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
The addition of capivasertib to fulvestrant improves time to second progression (PFS2) and time to first subsequent chemotherapy or death (TTFSC) in PIK3CA/AKT1/PTEN-altered patients with HR+/HER2- advanced breast cancer and the overall population, suggesting a clinically meaningful benefit when compared with placebo plus fulvestrant, as shown in the phase III CAPItello-291 trial.
Capivasertib‒fulvestrant combo delays second progression, chemo in advanced breast cancer
20 May 2026
Lecanemab continues to delay progression in AD at 4 years
The 48-month analysis of the global phase III Clarity AD study shows that lecanemab continues to deliver benefit and delay progression in early Alzheimer's disease (AD).
Lecanemab continues to delay progression in AD at 4 years
20 May 2026
Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer
In the PREcoopERA window-of-opportunity trial, the selective estrogen receptor degrader (SERD) giredestrant shows robust anticancer activity, either alone or in combination with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin, in premenopausal women with ER+/HER2– operable invasive breast cancer.
